
News|Articles|October 1, 2006
Pipeline Preview (October 2006)
Dalteparin (Fragmin, Pfizer) for the extended treatment of symptomatic venous thromboembolism (proximal deep vein thrombosis and/or pulmonary embolus) to prevent recurrent venous thromboembolism in patients with cancer
Advertisement
Recommendations for approval
Recommendations against approval
Nonapprovable designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The FDA proposes ditching comparative efficacy studies for biosimilars
2
Immune system targets single beta cells before Type 1 diabetes symptoms show
3
Winter exposes how closely eczema, asthma and allergies are linked
4
Misdiagnosis of Type 1 diabetes remains a major problem, despite advances
5

















































